Arrowhead Pharmaceuticals, Inc. (ARWR)Healthcare | Biotechnology | Pasadena, United States | NasdaqGS
84.91 USD
-3.68
(-4.154%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 84.80 -0.11 (-0.110%) ⇩ (Aug. 28, 2026, 7:54 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 5:55 a.m. EDT
Arrowhead Pharmaceuticals presents a compelling turnaround narrative, yet the recent price action tells a complex story. Despite a massive 171% revenue growth rate and a fortress-like balance sheet with $1.6 billion in cash, the stock has endured four consecutive years of annual price declines leading into 2025. This multi-year underperformance triggers a caution flag, capping the long-term outlook despite the exceptional top-line expansion. However, the current price action reflects a sharp re-rating, moving from 2025 lows of roughly $21 to the current $87 level, driven by positive Phase 3 trial results and a successful transition to a commercial entity. Short-term momentum is building, supported by a strong 50-day average crossover and analyst upgrades, but the lack of profitability and negative free cash flow prevent a top-tier long-term rating. Investors should view this as a high-risk, high-reward speculative play on the commercialization of their pipeline rather than a stable income generator. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.063553 |
| MSTL | 0.064149 |
| AutoTheta | 0.067633 |
| AutoETS | 0.069265 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 34% |
| H-stat | 4.53 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.024 |
| Excess Kurtosis | -0.25 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 295.984 |
| Revenue per Share | 4.766 |
| Market Cap | 11,960,170,496 |
| Forward P/E | -17.44 |
| Beta | 1.29 |
| Profit Margins | -47.79% |
| Website | https://arrowheadpharma.com |
As of Aug. 22, 2026, 5:55 a.m. EDT: Implied volatility remains elevated across all expirations, ranging from 53% to 66%, signaling heightened uncertainty surrounding the commercial transition. While call open interest builds at strikes above the current price ($100+), near-term put volume is disproportionately heavy at lower strikes ($50), suggesting traders are placing a floor on downside risk. The mix indicates a speculative stance where investors are betting on upside potential from recent trial wins while hedging against execution delays.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.4497664 |
| Address1 | 177 East Colorado Boulevard |
| Address2 | Suite 700 |
| All Time High | 2,925.0 |
| All Time Low | 1.2 |
| Ask | 91.2 |
| Ask Size | 2 |
| Audit Risk | 10 |
| Average Daily Volume10 Day | 987,710 |
| Average Daily Volume3 Month | 2,035,795 |
| Average Volume | 2,035,795 |
| Average Volume10Days | 987,710 |
| Beta | 1.294 |
| Bid | 79.65 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 3.298 |
| City | Pasadena |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 84.91 |
| Current Ratio | 5.899 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 87.855 |
| Day Low | 84.195 |
| Debt To Equity | 295.984 |
| Display Name | Arrowhead Pharmaceuticals |
| Earnings Call Timestamp End | 1,785,873,600 |
| Earnings Call Timestamp Start | 1,785,873,600 |
| Earnings Timestamp | 1,785,873,600 |
| Earnings Timestamp End | 1,795,550,400 |
| Earnings Timestamp Start | 1,795,550,400 |
| Ebitda | -200,635,008 |
| Ebitda Margins | -0.29968 |
| Enterprise To Ebitda | -58.694 |
| Enterprise To Revenue | 17.589 |
| Enterprise Value | 11,775,973,376 |
| Eps Current Year | -3.50545 |
| Eps Forward | -4.86803 |
| Eps Trailing Twelve Months | -2.18 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 626 304 3401 |
| Fifty Day Average | 83.5209 |
| Fifty Day Average Change | 1.3891068 |
| Fifty Day Average Change Percent | 0.016631847 |
| Fifty Two Week Change Percent | 244.97664 |
| Fifty Two Week High | 95.49 |
| Fifty Two Week High Change | -10.579994 |
| Fifty Two Week High Change Percent | -0.11079688 |
| Fifty Two Week Low | 22.73 |
| Fifty Two Week Low Change | 62.180004 |
| Fifty Two Week Low Change Percent | 2.735592 |
| Fifty Two Week Range | 22.73 - 95.49 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 756,052,200,000 |
| Float Shares | 122,449,260 |
| Forward Eps | -4.86803 |
| Forward P E | -17.442375 |
| Free Cashflow | -48,628,124 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 711 |
| Fullday Change | -3.67999 |
| Fullday Change Percent | -4.15396 |
| Fullday Price | 84.8 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 1.0 |
| Gross Profits | 669,494,976 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03657 |
| Held Percent Institutions | 0.85599 |
| Implied Shares Outstanding | 140,857,021 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://www.arrowheadresearch.com/invest.html |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,759,190,400 |
| Last Split Date | 1,321,488,000 |
| Last Split Factor | 1:10 |
| Long Business Summary | Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California. |
| Long Name | Arrowhead Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 11,960,170,496 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_203142 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -319,955,008 |
| Next Fiscal Year End | 1,790,726,400 |
| Non Diluted Market Cap | 12,509,495,597 |
| Number Of Analyst Opinions | 11 |
| Open | 87.76 |
| Operating Cashflow | -59,055,000 |
| Operating Margins | -2.26028 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 626 304 3400 |
| Post Market Change | -0.11000061 |
| Post Market Change Percent | -0.12954965 |
| Post Market Price | 84.8 |
| Post Market Time | 1,787,961,294 |
| Previous Close | 88.59 |
| Price Eps Current Year | -24.222284 |
| Price Hint | 2 |
| Price To Book | 25.745907 |
| Price To Sales Trailing12 Months | 17.864466 |
| Profit Margins | -0.4779 |
| Quick Ratio | 5.706 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -3.67999 |
| Regular Market Change Percent | -4.15396 |
| Regular Market Day High | 87.855 |
| Regular Market Day Low | 84.195 |
| Regular Market Day Range | 84.195 - 87.855 |
| Regular Market Open | 87.76 |
| Regular Market Previous Close | 88.59 |
| Regular Market Price | 84.91 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 1,282,091 |
| Return On Assets | -0.08104 |
| Return On Equity | -0.55207 |
| Revenue Growth | 1.71 |
| Revenue Per Share | 4.766 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 1 |
| Shares Outstanding | 140,857,021 |
| Shares Percent Shares Out | 0.0652 |
| Shares Short | 9,207,426 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 9,635,297 |
| Short Name | Arrowhead Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.0907 |
| Short Ratio | 4.8 |
| Source Interval | 15 |
| State | CA |
| Symbol | ARWR |
| Target High Price | 126.0 |
| Target Low Price | 100.0 |
| Target Mean Price | 110.18182 |
| Target Median Price | 104.0 |
| Total Cash | 1,597,859,968 |
| Total Cash Per Share | 11.312 |
| Total Debt | 1,379,405,056 |
| Total Revenue | 669,494,976 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.18 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 69.8222 |
| Two Hundred Day Average Change | 15.087807 |
| Two Hundred Day Average Change Percent | 0.21608897 |
| Type Disp | Equity |
| Volume | 1,282,091 |
| Website | https://arrowheadpharma.com |
| Zip | 91,105 |